Not affiliated with Eli Lilly or any pharmaceutical manufacturer. Retatrutide has not been approved by the FDA for any use. This website is for educational purposes only.

Retatrutide Journal

News, Research, and Obesity Insights

A plain-language reference on retatrutide (LY3437943): trial data, mechanism, and how it compares to semaglutide and tirzepatide.

Retatrutide 2026: what it is and everything confirmed so far

Study Results

Retatrutide 2026: Everything Confirmed So Far

October 2026: what retatrutide is, how it works, what its five Phase 3 trials found, and where it stands with the FDA.

Retatrutide vs Foundayo (Orforglipron): Injection or Pill for Weight Loss?

28% vs 11% weight loss. One is coming. One is already here. Here's what the data says.

RetaWeightLoss.com

October 3, 2026

Retatrutide TRIUMPH-1: Biggest Obesity Trial Result 2026

Study Results

Retatrutide TRIUMPH-1 Results: 28.3% Weight Loss in 2,339 Patients — Full Breakdown

TRIUMPH-1 met all primary endpoints: 28.3% average weight loss in 2,339 patients, 45.3% losing ≥30%, and 30.3% at 104 weeks. Here's what the data means.

RetaWeightLoss.com

October 3, 2026

Retatrutide Cost in 2028: $1,500/Month — Unless You Plan Now

Retatrutide Overview

How Much Will Retatrutide Cost? Insurance & Affordability Guide (2028)

Retatrutide is projected to cost $1,200-$1,500 per month when it launches (realistically late 2027 to mid-2028), based on current GLP-1 medication pricing patterns. This comprehensive guide covers insurance coverage expectations, patient assistance programs, and practical strategies to reduce your out-of-pocket costs from thousands to as little as $25 per month.

RetaWeightLoss.com

October 3, 2026